



Open Access

REVOLUTION OF 3D PRINTING IN PHARMACEUTICALS: INNOVATIONS, APPLICATIONS, AND FUTURE PERSPECTIVES

Sanket J Soni*¹, Ankitkumar N Patel²¹Associate Director, Department of Project and Portfolio Management, Amneal Pharmaceuticals, New Jersey, USA.² Director of Formulation, Department of Formulation R&D, Amneal Pharmaceuticals, New Jersey, USA.

Article History

Received on: 23-07-2024

Revised on: 18-09-2024

Accepted on: 22-10-2024



Abstract

3D printing, or additive manufacturing, is transforming the pharmaceutical industry by enabling the precise fabrication of complex drug formulations, personalized dosages, and advanced drug delivery systems. Initially utilized in aerospace and automotive industries, 3D printing has rapidly been adopted in pharmaceuticals, offering new opportunities for customized medicine, rapid prototyping, and on-demand drug manufacturing. This review explores the current advancements in 3D printing technologies, such as Fused Deposition Modelling (FDM), Stereo lithography (SLA), Selective Laser Sintering (SLS), Inkjet Printing, and Extrusion-Based Printing. These technologies have shown significant potential in creating personalized medication, developing complex drug delivery systems, and addressing paediatric and geriatric populations' unique needs. Despite these advancements, challenges still need to be addressed, including regulatory hurdles, technical limitations, scalability issues, and intellectual property concerns. Future directions include integrating 3D printing with digital health technologies for real-time patient monitoring and personalized treatment, developing advanced materials and printing technologies, and evolving regulatory frameworks to accommodate the growing use of 3D printing in pharmaceuticals. Collaborative research and development are crucial to overcoming these challenges and realizing the full potential of 3D printing in revolutionizing drug manufacturing and delivery, particularly in improving global accessibility to essential medicines.

Keywords: 3D Printing, Pharmaceuticals, Personalized Medicine, Drug Delivery, Additive Manufacturing

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2024 Author(s) retains the copyright of this article.



*Corresponding Author

Sanket J Soni

DOI: <https://doi.org/10.46795/ijhcb.v5i4.633>

Introduction

3D printing, also known as additive manufacturing, is a technology that constructs objects layer by layer based on digital models. Initially used in aerospace and automotive manufacturing industries, 3D printing has rapidly expanded into the medical field, including pharmaceuticals. In the pharmaceutical industry, 3D printing enables the precise fabrication of drug formulations with complex structures, customized dosages, and tailored release profiles [1]. This technology allows for the creation of personalized medicine, where drug formulations can be adapted to meet the specific

needs of individual patients, improving therapeutic outcomes and minimising side effects [2].

The adoption of 3D printing in pharmaceuticals began gaining traction in the early 21st century, with significant milestones marking its progress. One of the earliest breakthroughs was the FDA's approval of Spritam® in 2015, the first 3D-printed drug to reach the market. This drug, used to treat epilepsy, showcased the potential of 3D printing for producing rapidly dissolving oral dosage forms with precise dosage control. Since then, advancements in 3D printing technologies, such as Fused Deposition Modeling (FDM) and Stereolithography (SLA), have enabled the development of increasingly complex and customised drug delivery systems. These innovations have paved the way for the integration of 3D printing into mainstream pharmaceutical manufacturing, offering new possibilities for personalised medicine, on-demand drug

production, and the creation of novel drug delivery mechanisms [3,4].

2. Purpose and Scope of the Review

The primary purpose of this review is to examine the latest advancements in 3D printing technology as applied to the pharmaceutical industry. This includes an in-depth exploration of how 3D printing revolutionises drug formulation, manufacturing, and delivery. This review aims to provide a comprehensive understanding of how 3D printing is being leveraged to create more personalised, efficient, and effective pharmaceutical products by highlighting the cutting-edge techniques and innovations that have emerged in recent years. The review will also address the technological, regulatory, and clinical challenges associated with these advancements, offering insights into the future potential and ongoing developments in this rapidly evolving field.

3. 3D Printing Technologies in Pharmaceuticals

Fused Deposition Modeling (FDM)

Fused Deposition Modeling (FDM) is a widely used 3D printing technique that involves the extrusion of thermoplastic polymers layer by layer to build a three-dimensional structure. In pharmaceutical manufacturing, FDM is particularly useful for creating solid oral dosage forms, such as tablets, with customized shapes, sizes, and drug release profiles [4]. The technology allows for the incorporation of multiple active pharmaceutical ingredients (APIs) within a single tablet, enabling the production of personalized medicines tailored to the specific needs of patients. FDM's ability to precisely control the deposition of materials also makes it ideal for producing complex drug delivery systems that offer controlled and sustained release [5].

Stereolithography (SLA)

Stereolithography (SLA) is a 3D printing technique that uses a laser to cure and solidify layers of photosensitive resin, creating highly detailed and accurate three-dimensional structures. In pharmaceuticals, SLA is used to fabricate complex drug delivery systems, such as implants and microcapsules that require intricate geometries and precise control over drug release rates. SLA's high resolution and accuracy make it suitable for developing personalised drug delivery devices tailored to deliver drugs at specific rates and locations within the body, enhancing therapeutic efficacy and minimizing side effects [6].

Selective Laser Sintering (SLS)

Selective Laser Sintering (SLS) is a 3D printing technology that utilizes a laser to sinter powdered materials, fusing them to create solid structures. In the pharmaceutical industry, SLS fabricates porous drug formulations and controlled-release systems. The ability to create highly porous structures with SLS is particularly advantageous for developing dosage forms that require rapid or sustained drug release. The porosity of the printed structures can be precisely controlled, allowing for the design of drug delivery systems that release the active

ingredient at a predetermined rate, improving patient adherence and therapeutic outcomes [7].

Inkjet Printing

Inkjet printing is a versatile 3D printing technology that involves the precise deposition of small droplets of drug solutions onto substrates to create dosage forms. This technique is used in pharmaceuticals to tailor doses and create multi-drug combinations within a single dosage form. Inkjet printing allows for the production of highly personalized medications, where the dose of each drug can be adjusted to meet the specific needs of individual patients. Additionally, it enables the creation of dosage forms with complex release profiles, combining immediate and controlled-release layers in a single tablet [8].

Extrusion-Based Printing

Extrusion-based printing is a 3D printing technique that involves the extrusion of semi-solid materials, such as hydrogels or pastes, to create three-dimensional structures. This technology is used in pharmaceutical applications to produce personalized medicine and complex dosage forms, such as multi-layer tablets or drug-loaded scaffolds. Extrusion-based printing is particularly beneficial for creating formulations that require a high degree of customization, such as those needed for pediatric or geriatric patients. The technique also allows for the incorporation of multiple drugs within a single dosage form, enabling combination therapies tailored to individual patient needs [9].

Table 1: 3D Printing Technologies in Pharmaceuticals

3D Printing Technology	Description	Applications in Pharmaceuticals
Fused Deposition Modeling (FDM)	Extrudes thermoplastic polymers layer by layer to create solid structures.	Creating solid oral dosage forms with customized shapes, sizes, and drug release profiles.
Stereolithography (SLA)	Uses a laser to cure photosensitive resin, creating detailed 3D structures.	Fabricating complex drug delivery systems, such as implants and microcapsules.
Selective Laser Sintering (SLS)	Utilizes a laser to sinter powdered materials into solid structures.	Fabricating porous drug formulations and controlled release systems.
Inkjet Printing	Deposits small droplets of drug solutions to create dosage forms.	Tailoring drug doses and creating multi-drug combinations in a single dosage form.
Extrusion-Based	Extrudes	Creating

Printing	semi-solid materials to create three-dimensional structures.	personalized medicine and complex dosage forms, such as multi-layer tablets.
----------	--	--

3D printing technologies have significantly transformed pharmaceutical manufacturing by enabling the precise and customizable production of drug formulations. Each 3D printing method offers unique advantages and applications. Fused Deposition Modeling (FDM) is widely used for creating solid dosage forms with tailored release profiles, making it ideal for producing personalized medications. Stereolithography (SLA) excels in fabricating intricate and complex drug delivery systems, such as those with multi-layered or compartmentalised structures,

allowing for controlled and targeted drug release. Selective Laser Sintering (SLS) is particularly useful for producing porous formulations, enhancing drug dissolution and providing controlled release properties. Inkjet Printing is notable for its ability to accurately deposit small quantities of drugs, making it suitable for creating individualised doses and combining multiple drugs into a single dosage form. Lastly, Extrusion-Based Printing is employed to produce complex dosage forms, including multi-drug tablets and implants, with precise control over drug composition and release characteristics. These technologies collectively offer unprecedented flexibility and precision in drug manufacturing, paving the way for highly personalized and effective treatments [10-12].

Table 2: Advantages and Disadvantages of 3D Printing Technologies in Pharmaceuticals

3D Printing Technology	Advantages	Disadvantages	Marketed Products
Fused Deposition Modeling (FDM)	Cost-effective, easy to implement, customizable dosing.	Limited to thermoplastic materials; resolution may not be sufficient for all applications.	-
Stereolithography (SLA)	High precision, ability to create intricate structures.	Requires photopolymerizable materials; expensive equipment.	-
Selective Laser Sintering (SLS)	Allows for controlled porosity, suitable for creating slow-release formulations.	Limited material choices, high energy consumption, and longer production times.	-
Inkjet Printing	Precise dosing and the ability to create multi-drug combinations.	They are limited to low-viscosity liquids and potential clogging issues.	-
Extrusion-Based Printing	Versatile, can produce complex structures, high drug load capacity.	Limited by material properties; slower production speed.	Spritam® (Aprecia Pharmaceuticals)

Brief Explanation of Marketed Products

Spritam®, developed by Aprecia Pharmaceuticals, is the first FDA-approved 3D-printed drug produced using ZipDose® technology, an example of Extrusion-Based Printing. It is a rapidly disintegrating tablet used for the treatment of epilepsy, showcasing the potential of 3D printing to create tailored and patient-specific dosage forms. Although other technologies like FDM, SLA, SLS, and Inkjet Printing are actively researched and applied in pharmaceutical development, they have yet to see the same level of commercialized success as Extrusion-Based Printing in terms of marketed products. However, these technologies are promising for future personalized and complex drug delivery systems applications [13].

4. Benefits of 3D Printing in Pharmaceuticals Personalised Medicine

3D printing allows for the precise customization of drug doses and formulations tailored to the specific needs of individual patients. By adjusting the dosage and drug release profiles and even combining multiple medications into a single dosage form, 3D printing enables the creation of highly personalized treatments [14]. This is particularly beneficial for patients with unique therapeutic needs, such as those requiring specific dosages unavailable in

standard forms or those with conditions requiring a combination of drugs. Personalized medicine through 3D printing promises to enhance therapeutic outcomes, reduce side effects, and improve patient adherence to treatment plans [15].

Complex Drug Delivery Systems

3D printing facilitates the development of complex drug delivery systems, such as multi-layer tablets, implants, and other advanced mechanisms that control the release of drugs over time or target specific areas within the body [16]. These systems can be designed to release drugs at different rates or sequences, providing more effective and sustained treatment for various conditions. By enabling the creation of intricate structures that would be challenging or impossible to produce with traditional manufacturing methods, 3D printing is advancing drug delivery capabilities, leading to more efficient and targeted therapies [17].

Rapid Prototyping and Drug Development

3D printing accelerates the drug development process by enabling rapid prototyping and iteration. Researchers can quickly produce and test different drug formulations and delivery systems, allowing for faster optimisation and refinement of drug products. This speed and flexibility

reduce the time and cost of bringing new drugs to market, as developers can efficiently assess the feasibility and effectiveness of various designs before proceeding to large-scale production. Rapid prototyping through 3D printing thus plays a crucial role in innovation and shortening the drug development timeline [18].

Paediatric and Geriatric Medicine

3D printing is particularly advantageous for developing drug forms tailored to the needs of paediatric and geriatric populations, which often require specialised dosages and formulations. For children, 3D printing can produce smaller, flavoured, or easy-to-swallow tablets, making medication administration more manageable and improving adherence. For the elderly, who may have difficulty swallowing or require lower or divided doses, 3D printing can create dosage forms that are easier to take and better suited to their physiological needs. This adaptability ensures that vulnerable populations receive the appropriate medication in the most effective form [19].

On-Demand Drug Manufacturing

On-demand drug manufacturing using 3D printing allows for the production of medications tailored to patient’s immediate needs at the point of care, such as in hospitals or pharmacies. This approach reduces the need for large inventories, minimises waste, and improves access to medications, especially in remote or underserved areas. By producing drugs as needed, on-demand manufacturing ensures that patients receive fresh and customised medications promptly, enhancing the efficiency and responsiveness of healthcare delivery systems [20].

Table 2: Benefits of 3D Printing in Pharmaceuticals

Application	Benefits	Examples/Impact
Personalized Medicine	Enhanced therapeutic outcomes, reduced side effects, and improved adherence.	Tailored dosages and combination pills for specific patient profiles.
Complex Drug Delivery Systems	Controlled drug release, targeted therapy, and sustained treatment effects.	Multi-layer tablets, time-release implants.
Rapid Prototyping and Drug Development	Faster optimisation, reduced time and cost to market.	Rapid testing of drug formulations and faster development cycles.
Pediatric and Geriatric Medicine	Improved medication adherence, safer and more effective dosing.	Child-friendly formulations, easy-to-swallow tablets for elderly patients.

On-Demand Drug Manufacturing	Immediate availability, reduced waste, better resource management.	In-hospital or pharmacy drug production, customized medications on demand.
------------------------------	--	--

5. Challenges and Limitations

Regulatory Challenges

The regulatory landscape for 3D printed drugs is still evolving, presenting significant challenges for their approval and widespread adoption. Current regulatory frameworks, such as those set by the FDA and EMA, were developed with traditional pharmaceutical manufacturing processes in mind and may not fully account for the unique aspects of 3D printing [21]. These challenges include validating the consistency and safety of 3D printed drugs, establishing standards for the raw materials used in printing, and ensuring that printed products meet stringent quality requirements. Moreover, the ability to produce personalized and on-demand medications further complicates regulatory oversight, as each printed drug could be considered a unique product. Navigating these regulatory hurdles requires close collaboration between manufacturers, regulatory bodies, and healthcare providers to develop guidelines that ensure patient safety while fostering innovation [22].

Technical Limitations

3D printing in pharmaceuticals faces several technical limitations, particularly in material compatibility, printing resolution, and reproducibility. Not all pharmaceutical ingredients are suitable for 3D printing, as they may not possess the necessary thermal or mechanical properties to be processed by printing technologies like FDM or SLS. Additionally, the resolution of 3D printers, which determines the precision of the printed drug’s structure, can vary, affecting the consistency and accuracy of drug dosage and release profiles. Reproducibility is another critical issue, as slight variations in the printing process can lead to significant differences in the final product’s quality and efficacy. These technical challenges must be addressed to ensure that 3D-printed drugs can be produced reliably and at the high standards required for clinical use [23, 24].

Scalability

While 3D printing offers tremendous flexibility for producing small batches of personalized medicines, scaling up this technology for mass production presents significant challenges. Traditional pharmaceutical manufacturing processes are designed for high-volume production, where economies of scale reduce costs and ensure consistency across large batches [24]. In contrast, 3D printing is inherently slower and less suited to producing large quantities of identical products. Scaling up 3D printing would require significant advances in printer speed, automation, material handling, and the development of new production models that can integrate 3D printing into large-scale operations. Without these

advancements, the widespread use of 3D printing in mainstream pharmaceutical manufacturing may remain limited [25-27].

Quality Control

Ensuring the consistency and quality of 3D-printed pharmaceuticals is a critical challenge that affects their safety and efficacy. Unlike traditional manufacturing, where quality control is applied uniformly across large batches, 3D printing requires individualized quality assessment for each printed product, especially when producing personalized medicines. Variations in printer performance, material properties, and environmental conditions during printing can all impact the final product's quality [26]. To address these issues, robust quality control processes must be developed, including real-time monitoring of the printing process, post-printing inspection techniques, and the validation of each printed drug's properties. Implementing these quality control measures is essential to gaining regulatory approval and ensuring that 3D-printed drugs meet the high standards required for patient use [28-30].

Intellectual Property Concerns

The rise of 3D printing in pharmaceuticals introduces new intellectual property (IP) challenges, particularly regarding the patenting and protection of drug designs. Traditional pharmaceutical patents typically cover the chemical composition of a drug or its method of manufacture, but 3D-printed drugs may involve complex designs and digital blueprints that are not easily covered by existing IP laws. The potential for digital blueprints to be shared, modified, or reproduced without authorization raises concerns about the protection of proprietary drug formulations and designs. Furthermore, as 3D printing enables the customization of drugs at the point of care, it may blur the lines of patent infringement, making it difficult to enforce IP rights. Addressing these legal issues requires updating IP laws to reflect the unique challenges posed by 3D printing and ensuring that innovators can protect their inventions while fostering the technology's growth [30-34].

Table 3: Challenges and Limitations

Challenge/Limitation	Impact	Examples/Considerations
Regulatory Challenges	Delays in product approval, need for new guidelines.	FDA/EMA regulations, personalized medicine complicating approval.
Technical Limitations	Affects drug quality, consistency, and applicability of 3D printing.	Limited material choices and variations in drug dosage due to resolution.
Scalability	Limits the ability to mass-produce 3D-	Slow production speed, need for advanced

	printed drugs economically.	automation and printer improvements.
Quality Control	Critical for safety and efficacy, impacts regulatory approval.	Real-time process monitoring and individualized quality assessment.
Intellectual Property Concerns	Complicates IP enforcement and risks to proprietary drug formulations.	Digital blueprint piracy and the need for updated IP laws for 3D printing.

6. Future Directions

As 3D printing technology advances, its integration with digital health technologies is poised to revolutionize personalized medicine. By combining 3D printing with real-time patient monitoring systems, healthcare providers can tailor treatments more precisely to individual needs. For example, data collected from wearable devices and health apps can inform the creation of customized drug formulations that address the patient's condition and adjust as needed. This synergy between 3D printing and digital health could lead to a new era of personalized treatment plans, where medications are printed on demand based on up-to-the-minute health data, ensuring optimal therapeutic outcomes and minimizing adverse effects.

In addition to technological integration, the future of 3D printing in pharmaceuticals will be shaped by the development of advanced materials and the evolution of regulatory frameworks. New biocompatible and biodegradable materials and novel printing technologies will expand the capabilities of 3D printing, enabling the production of more complex and effective drug delivery systems. Regulatory bodies are also expected to evolve, developing new policies addressing the unique challenges and opportunities of 3D-printed drugs. Collaborative research and development involving partnerships between academia, industry, and regulatory agencies will drive innovation and ensure that 3D printing technologies are safely and effectively integrated into mainstream pharmaceutical manufacturing. Additionally, 3D printing holds significant potential to democratize drug production, making it possible to produce medicines locally in low-resource settings, thereby improving access to essential medications and addressing global health disparities.

7. Conclusion

The advent of 3D printing in the pharmaceutical industry marks a significant leap forward in drug manufacturing and delivery. This technology's ability to produce complex, personalized, and on-demand medications offers immense potential for improving patient outcomes and addressing unmet medical needs. As demonstrated by various 3D

printing techniques, including FDM, SLA, SLS, Inkjet Printing, and Extrusion-Based Printing, the scope of applications is vast, from personalized medicine to complex drug delivery systems and rapid prototyping. However, the industry must overcome several challenges to harness these capabilities fully. Regulatory frameworks must evolve to ensure the safety and efficacy of 3D-printed drugs, while technical limitations related to material compatibility, printing resolution, and scalability must be addressed. Quality control is another critical aspect that requires robust protocols to ensure consistency and safety in personalized medicine. Intellectual property concerns, particularly related to the protection of digital blueprints and designs, also need to be resolved. Looking ahead, the integration of 3D printing with digital health technologies and the development of new materials will further expand its applications, potentially democratizing drug production and improving access to essential medicines worldwide. Through continued research, collaboration, and innovation, 3D printing is poised to revolutionize the pharmaceutical industry, bringing us closer to a future where personalized, efficient, and accessible healthcare is a reality for all.

Funding

No

Acknowledgement

Nil

Conflict of Interest

No conflict of interest.

Informed Consent

Not applicable.

Ethical Statement

Not applicable.

Author Contribution

Sanket J Soni, Ankitkumar N Patel both are contributed equally.

References

1. Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Adv Drug Deliv Rev.* 2017;108:39-50.
2. Wang J, Goyanes A, Gaisford S, Basit AW. Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. *Int J Pharm.* 2016;503(1-2):207-212.
3. Goyanes A, Buanz AB, Basit AW, Gaisford S. Fused-filament 3D printing (3DP) for fabrication of tablets. *Int J Pharm.* 2014;476(1-2):88-92.
4. Aprecia Pharmaceuticals Company. Spritam® (levetiracetam) tablets. [Internet]. Available from: <https://www.aprecia.com>
5. Chai X, Chai H, Wang X, Yang J, Li J, Zhao Y, et al. Design of a 3D-printed gastric floating sustained-release delivery system for oral administration of rabeprazole sodium. *Int J Pharm.* 2017;552(1-2):281-290.
6. Awad A, Fina F, Trenfield SJ, et al. 3D printed pellets (miniprintlets) for oral delivery of low-dose drugs. *Int J Pharm.* 2019;569:118581.
7. Jamróz W, Szafraniec J, Kurek M, Jachowicz R. 3D printing in pharmaceutical and medical applications – recent achievements and challenges. *Pharm Res.* 2018;35(9):176.
8. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *J Control Release.* 2015;217:308-314.
9. Yu DG, Shen X, Branford-White C, White K, Zhu LM, Bligh SW. Oral fast-dissolving drug delivery membranes prepared from electrospun polyvinylpyrrolidone ultrafine fibers. *Nanotechnology.* 2009;20(5):055104.
10. Scoutaris N, Ross SA, Douroumis D. Current trends on the role of 3D printing in drug delivery. *Expert Opin Drug Deliv.* 2018;15(5):433-450.
11. Melocchi A, Parietti F, Loreti G, et al. 3D printing by fused deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of drugs. *J Drug DelivSci Technol.* 2015;30:360-367.
12. Prasad LK, Smyth H. 3D Printing technologies for drug delivery: a review. *Drug Dev Ind Pharm.* 2016;42(7):1019-1031.
13. Sun Y, Soh S. Printing Tablets with Fully Customizable Release Profiles for Personalized Medicine. *Adv Mater.* 2015;27(47):7847-7853.
14. Mathew E, Domínguez-Robles J, Larrañeta E, Lamprou DA. Fused deposition modeling as a potential tool for anti-infective dialysis catheter fabrication. *Macromol Biosci.* 2019;19(2):1800421.
15. Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. *AAPS PharmSciTech* 19, 1358–1366 (2018).
16. Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. *Chromatographia* 80, 1211–1224 (2017).
17. Chowdary KP, Chandra DU, Mahesh N, Reddy TM, Gopaiah KV. Enhancement of dissolution rate and formulation development of pioglitazone-a BCS class II drug. *J. Pharm. Res.* 2011 Nov;4:3862-3.

18. Chia HN, Wu BM. Recent advances in 3D printing of biomaterials. *J Biol Eng.* 2015;9(1):1-14.
19. Dodziuk H. Applications of 3D printing in healthcare. *KardiochirTorakochirurgia Pol.* 2016;13(3):283-293.
20. Ventola CL. Medical applications for 3D printing: current and projected uses. *P T.* 2014;39(10):704-711.
21. Trenfield SJ, Awad A, Madla CM, et al. Shaping the future: recent advances of 3D printing in drug delivery and healthcare. *Expert Opin Drug Deliv.* 2019;16(10):1081-1094.
22. Klein GT, Lu Y, Wang MY. 3D printing and neurosurgery—ready for prime time? *World Neurosurg.* 2013;80(3-4):233-235.
23. Walker S, Bøtker JP, Bokser AD, et al. Pharma 4.0: an augmented reality solution for next-generation pharmaceutical manufacturing. *Int J Pharm.* 2019;566:646-656.
24. Sadia M, Sośnicka A, Arafat B, et al. Adaptation of pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate release tablets. *Int J Pharm.* 2016;513(1-2):659-668.
25. Kakulamarri PR, Alikatte KL, Mateti UV (2016) Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. *J Pharm Drug Deliv Res* 5:3
26. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. *future.*;1:6.
27. Zhang J, Vo AQ, Feng X, Bandari S, Repka MA. Pharmaceutical Additive Manufacturing: A Novel Tool for Complex and Personalized Drug Delivery Systems. *AAPS PharmSciTech.* 2018;19(8):3388-3402.
28. Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Adv Drug Deliv Rev.* 2017;108:39-50.
29. Lim SH, Kathuria H, Tan JY, Kang L. 3D printed drug delivery and testing systems—a passing fad or the future? *Adv Drug Deliv Rev.* 2018;132:139-168.
30. Sun Y, Soh S. Printing Tablets with Fully Customizable Release Profiles for Personalized Medicine. *Adv Mater.* 2015;27(47):7847-7853.
31. Caplin NJ, Colombo P, Sonvico F. 3D printing of inhalable dry powder medicines: A regulatory perspective. *J Aerosol Med Pulm Drug Deliv.* 2018;31(1):55-69.
32. Liang K, Carmone S, Brambilla D, Leroux JC. 3D printing of a wearable personalized oral delivery device: A first-in-human study. *Sci Adv.* 2018;4(5)
33. Daly R, Harrington TS, Martin GD, Hutchings IM. Inkjet printing for pharmaceuticals—A review of research and manufacturing. *Int J Pharm.* 2015;494(2):554-567.
34. Katstra WE, Palazzolo RD, Rowe CW, et al. Oral dosage forms fabricated by three dimensional printing™. *J Control Release.* 2000;66(1):1-9.